Aspirin Protects Against Barrett's Esophagus in a Multivariate Logistic Regression Analysis

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 7, 2012, Pages 722-727

  Omer, Zehra B ^a   Ananthakrishnan, Ashwin N ^a,b   Nattinger, Kevin J ^a   Cole, Elisabeth B ^a   Lin, Jesse J ^a   Kong, Chung Yin ^a,b   Hur, Chin ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer risk; Esophagus; GERD; NSAID

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGE; ARTICLE; BARRETT ESOPHAGUS; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; ENDOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; RISK FACTOR; SEX; SMOKING;

AGED; ANTI-INFLAMMATORY AGENTS; ASPIRIN; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; CHEMOPREVENTION; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PREVALENCE;

EID: 84862646743     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.02.031     Document Type: Article

References (30)

1. American Cancer Society, ACS: cancer facts & figures 2012 2012, American Cancer Society, Atlanta.
2. Spechler S.J. Barrett's esophagus. Gastroenterologist 1994, 2:273-284.
3. Wang K.K., Sampliner R.E. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008, 103:788-797.
4. Inadomi J.M., Sampliner R., Lagergren J., et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003, 138:176-186.
5. Provenzale D., Schmitt C., Wong J.B. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999, 94:2043-2053.
6. Ouatu-Lascar R., Fitzgerald R.C., Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999, 117:327-335.
7. Neumann C.S., Iqbal T.H., Cooper B.T. Long term continuous omeprazole treatment of patients with Barrett's oesophagus. Aliment Pharmacol Ther 1995, 9:451-454.
8. Lao-Sirieix P., Roy A., Worrall C., et al. Effect of acid suppression on molecular predictors for esophageal cancer. Cancer Epidemiol Biomarkers Prev 2006, 15:288-293.
9. Kastelein F., Spaander M.C., Biermann K., et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology 2011, 141:2000-2008. quiz e13-e14.
10. Nguyen D.M., Richardson P., El-Serag H.B. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 2010, 138:2260-2266.
11. Shirvani V.N., Ouatu-Lascar R., Kaur B.S., et al. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000, 118:487-496.
12. Morris C.D., Armstrong G.R., Bigley G., et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001, 96:990-996.
13. Corley D.A., Kerlikowske K., Verma R., et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003, 124:47-56.
14. Jankowski J., Moayyedi P. Re: cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst 2004, 96:885-887. author reply 887.
15. Kandil H.M., Tanner G., Smalley W., et al. Cyclooxygenase-2 expression in Barrett's esophagus. Dig Dis Sci 2001, 46:785-789.
16. Abdalla S.I., Sanderson I.R., Fitzgerald R.C. Effect of inflammation on cyclooxygenase (COX)-2 expression in benign and malignant oesophageal cells. Carcinogenesis 2005, 26:1627-1633.
17. Wilson K.T., Fu S., Ramanujam K.S., et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998, 58:2929-2934.
18. Zimmermann K.C., Sarbia M., Weber A.A., et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999, 59:198-204.
19. Piazuelo E., Jimenez P., Lanas A. COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer. Curr Pharm Des 2003, 9:2267-2280.
20. Yachimski P., Lee R.A., Tramontano A., et al. Secular trends in patients diagnosed with Barrett's esophagus. Dig Dis Sci 2010, 55:960-966.
21. Naimi T.S., Brewer R.D., Mokdad A., et al. Binge drinking among US adults. JAMA 2003, 289:70-75.
22. Naimi T.S., Brown D.W., Brewer R.D., et al. Cardiovascular risk factors and confounders among nondrinking and moderate-drinking U.S. adults. Am J Prev Med 2005, 28:369-373.
23. Lieberman D., Fennerty M.B., Morris C.D., et al. Endoscopic evaluation of patients with dyspepsia: results from the national endoscopic data repository. Gastroenterology 2004, 127:1067-1075.
24. Ford A.C., Forman D., Reynolds P.D., et al. Ethnicity, sex, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol 2005, 162:454-460.
25. Cook M.B., Wild C.P., Forman D. A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease. Am J Epidemiol 2005, 162:1050-1061.
26. Labenz J., Jaspersen D., Kulig M., et al. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol 2004, 99:1652-1656.
27. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007, 41:131-137.
28. Adeniyi K.O. Gastric acid secretion and parietal cell mass: effect of sex hormones. Gastroenterology 1991, 101:66-69.
29. Anderson L.A., Johnston B.T., Watson R.G., et al. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res 2006, 66:4975-4982.
30. Thrift A.P., Pandeya N., Smith K.J., et al. The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus. Aliment Pharmacol Ther 2011, 34:1235-1244.